Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China

Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China. Using electronic medical records of sampled patients between 2011 and 2016...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2020-02, Vol.20 (1), p.131-131, Article 131
Main Authors: Xu, Ruihua, Wang, Wei, Zhu, Bo, Lin, Xiaoyan, Ma, Dong, Zhu, Lingjun, Zhao, Qingchuan, Nie, Yongzhan, Cai, Xiaohong, Li, Qi, Fang, Weijia, Li, Hongyan, Wang, Ning, Chen, Yun, Peng, Cike, Fang, Honghao, Shen, Lin
Format: Article
Language:English
Subjects:
5-Fluorouracil
Age
Biological products
Cancer
Cancer metastasis
Cancer patients
Cancer research
Cancer therapies
Care and treatment
Chemotherapy
China
Colorectal cancer
Colorectal carcinoma
Comparative analysis
Demography
Diseases
Electronic medical records
Electronic records
Epidemiology
Fluorouracil
Folinic acid
Hospitals
Insurance
Internal medicine
Irinotecan
Medical prognosis
Medical records
Medical research
Metastases
Metastasis
National health insurance
Oncology
Oxaliplatin
Patients
Population
Prognosis
Real-world evidence
Treatment patterns
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China. Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to describe demographics and disease prognosis of CRC patients, and examine treatment sequences among metastatic CRC (mCRC) patients. Descriptive, comparative and survival analyses were conducted. Among mCRC patients (3878/8136, 48%), the fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and other oxaliplatin-based regimens were the most widely-used first-line treatment (42%). Fluorouracil, leucovorin, irinotecan (FOLFIRI) and other irinotecan-based regimens dominated the second-line (40%). There was no a dominated regimen for the third-line. The proportion of patients receiving chemotherapy with targeted biologics increased from less than 20% for the first- and second- lines to 34% for the third-line (p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-020-6557-5